• Breaking

    18 May 2021

    Home COVAXIN Drug Approved For Phase2/3 Trials In 2-18 Years

    COVAXIN Drug Approved For Phase2/3 Trials In 2-18 Years

    Latest reports have been coming in from Ministry of Health and Family welfare where Dr V K Paul has said that the scientists will examine the drug in COVID-19 National Task Force for adding it to the treatment protocol. 

    Drugs Controller General of India (DCGI) has granted permission for emergency use as per reports by Dr. VK Paul, Member-Health, Niti Aayog on 'anti-COVID drug 2DG' developed by DRDO 

    Dr. VK Paul, Member-Health, Niti Aayog further added that the  COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. 

    I have been told that trials will begin in the next 10-12 days as per Dr. VK Paul, Member-Health, Niti Aayog.
    Tags
    Share This
    Author Image

    About Medianews18

    By at
    Labels: ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)

    Author Details

    Media News 18 provides information, the latest news and current events around India and the world. The purpose of the website is to give all the updates related to national, international happenings as soon as they break besides latest information on wide range of subjects including politics, entertainment, business, sports, health, science and technology, environment, economy etc that concern and interest our readers. Our aim is to bring forward the hidden questions related to these subjects which we cover, to analyse the political, social and economic scenario of the country and abroad honestly and with impunity.

    Pages